Eli Lilly to buy Ajax Therapeutics for up to 2.3 billion to push new oral myelofibrosis drug

A rare blood cancer gets an oral contender fast

Eli Lilly plans to acquire Ajax Therapeutics for up to $2.3 billion to develop a potential new oral treatment for myelofibrosis, a rare blood cancer. The company expects key clinical data in 2026 and intends to rapidly advance the program into larger trials, aiming to add another targeted option for patients and specialists.